A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation (AZALEA)
A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation (AZALEA)
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
Inclusion Criteria:
Male and female patients ≥ 55 years old
Patients with a history of atrial fibrillation (AF) or atrial flutter with planned indefinite anticoagulation
Patients with a CHA2DS2-VASc of ≥4 OR a CHA2DS2-VASc of ≥3 with at least 1 of the following:
Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply
Zamość, Lubusz Voivodeship 22-400, Poland
Seogu, Busan 49201, South Korea
Tiachung, TXG 404, Taiwan